Quotient Clinical announces new investment in Translational Pharmaceutics™
Quotient Clinical – the pioneer of Translational Pharmaceutics™ – has announced a significant expansion of its capacity and capabilities. This investment is a direct response to the rapid rate of adoption of the Company’s Translational Pharmaceutics platform and unique approach by a growing international client base.
Quotient Clinical announces RapidFACT™ collaboration with Pulmatrix to develop a new bronchodilator therapy for COPD
Quotient Clinical today announced a collaboration with Pulmatrix Inc, a Massachusetts’s based biotech company, to support the development of PUR0200. The new bronchodilator therapy for the treatment of chronic obstructive pulmonary disease (COPD) and the first small molecule product to emerge from Pulmatrix’s novel inhaled iSPERSETM technology platform.
Quotient Clinical announces the novel application of a 14C microdose study to establish the mass balance of Elacytarabine in healthy subjects
16 July 2013 – Quotient Clinical, a business unit of Quotient Bioresearch (“Quotient”) today announced the completion of a 14c microdose study to establish the mass balance of elacytarabine in healthy subjects. The study was conducted together with Clavis Pharma.
Quotient announces extension of RapidFACT™ into non-oral routes of delivery
Nottingham, U.K, (19th March 2013) –Quotient Clinical, part of Quotient Bioresearch (“Quotient”) today announced that three new pharma and biotech clients have selected its RapidFACT™ service to support the development of optimal drug products for pulmonary, transdermal, and ocular administration. This marks a key extension in the application of RapidFACT™ across a wide range of dosage forms and delivery routes.
Quotient Clinical, a Centre of Excellence for 14C enabled clinical drug development, provides innovative human ADME solutions for oncology molecules and inhaled products
4 March 2013 – Quotient Clinical, a business unit of Quotient Bioresearch (“Quotient”), today announced the completion of three significant clinical programs that emphasise its world leading position in 14C enabled clinical drug development.